Clinical trials: Malignancies Multiple
Nutritional Deficiency, Gastrointestinal Cancer
Effect of Silkworm Pupa Tablets in Gastrointestinal Malignancies at Nutritional Risk Following Radical Surgery
This is a randomized, double-blind, very low dose parallel-controlled, prospective, multi-center trial evaluating the improvement of nutritional status and frailty with silkworm pupa tablets after radical resection of…
- Conditions
- Nutritional Deficiency, Gastrointestinal Cancer, Frailty Syndrome
- Trial name
- NCT06551675
- Testing
- Silkworm pupa tablets, Control product
- Where
- 4 sites in China
- Volunteers
- 120 people
- Sponsor
- Xiaosun Liu, MD
Thymoma
Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
The purpose of this study is to determine whether postoperative conformal radiotherapy are effective in the treatment of Masaoka stage II-III B type thymoma.
- Trial name
- NCT02014805
- Testing
- radiotherapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Chinese Academy of Medical Sciences
Pulmonary Nodule, Multiple, Pulmonary Nodule, Solitary
Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region
GGO is a characteristic focus of early lung cancer. Due to the abundant peripheral blood vessels and bronchial tissues around the GGO lesions located in pulmonary hilar, only lobectomy could be used for the surgical treat of…
- Trial name
- NCT05477251
- Testing
- microwave ablation, lobectomy
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Anal Squamous Cell Carcinoma, Colorectal Neoplasms
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
REFIT-MSS is a non-randomized, multicenter, open-label, multi-cohort, 2-stage, phase II trial to evaluate the efficacy and safety of regorafenib in combination with tislelizumab (referred as Rego-Tisle) in adult patients with…
- Conditions
- Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma
- Trial name
- REFIT-MSS (NCT05582031)
- Testing
- Regorafenib in combination with Tislelizumab
- Sponsor
- Translational Research in Oncology
Multiple Myeloma
2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE
This study is being done in an attempt to improve the remission rate and the survival time for subjects with high-risk myeloma. It is hoped that by giving higher doses of commonly used chemotherapy drugs and by giving courses…
- Trial name
- NCT00577512
- Testing
- DTPACE
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Prostate Cancer
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
This proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a history of aggressive prostate cancer, in the tumor…
- Trial name
- PGV-Prostate (NCT05010200)
- Testing
- PGV-001, Poly-ICLC, CDX-301
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ashutosh Kumar Tewari
Breast Neoplasm, Colorectal Neoplasm
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
This trial studies how well a decision aid website works in helping to make decisions about fertility in participants with cancer.
- Conditions
- Breast Neoplasm, Colorectal Neoplasm, Female Reproductive System Neoplasm, Health Care Provider
- Trial name
- NCT03141437
- Testing
- Best Practice, Educational Intervention, Internet-Based Intervention
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Benign Prostatic Hyperplasia
Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)
Purpose: To evaluate the efficacy of prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH) and refractory lower urinary tract symptoms (LUTS) in decreasing the volume of the prostate gland.
- Trial name
- NCT02167919
- Testing
- Microspheres
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Plasma Cell Myeloma
Home Based Daratumumab Administration for Patients With Multiple Myeloma
This clinical trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma.
- Trial name
- NCT05511428
- Testing
- Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Thomas Jefferson University
Multiple Myeloma, Neoplasms
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
The purpose of this study is to see how long lenalidomide therapy can maintain or improve the disease response obtained after induction therapy that does not include lenalidomide, pomalidomide or thalidomide; and consequently…
- Conditions
- Multiple Myeloma, Neoplasms, Plasma Cells, Paraproteinemias
- Trial name
- NCT02155634
- Testing
- Lenalidomide
- Sponsor
- Celgene
Oral Mucositis
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy
- Trial name
- NCT01403064
- Testing
- ALD518, 0.9% saline
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 76 people
- Sponsor
- CSL Behring
Unresectable Metastatic Colorectal Cancer
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy
- Trial name
- alloSHRINK (NCT03692429)
- Testing
- CYAD-101, FOLFOX, FOLFIRI
- Where
- 4 sites in United States, Belgium
- Volunteers
- 49 people
- Sponsor
- Celyad Oncology SA
Cancer Related Pain
NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
This is a multi-centre, long term, double blind, clinical protocol for NanaBis™ as a monotherapy treatment in participants 18-75 years of age with cancer related pain.
- Trial name
- NCT04808531
- Testing
- NanaBis™, Oxycodone CR, Oxycodone IR
- Volunteers
- 360 people
- Sponsor
- Medlab Clinical
Multiple Myeloma
UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies
The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
- Trial name
- NCT00578045
- Testing
- Transfusion
- Where
- United States
- Sponsor
- University of Arkansas
Gastric Cancer
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
The aim of this study is to evaluate the efficacy and safety of combination therapy with ramucirumab, paclitaxel, and trastuzumab biosimilar as second line treatment of HER2 positive metastatic gastric cancer after failure of…
- Trial name
- NCT03766607
- Testing
- Trastuzumab, Ramucirumab, Paclitaxel
- Where
- South Korea
- Sponsor
- Korean South West Oncology Group
NSCLC Stage IV, Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
- Conditions
- NSCLC Stage IV, Brain Metastases, Immunotherapy
- Trial name
- NCT04291092
- Testing
- Immunotherapy, WBRT, Chemotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia, Plasma Cell Leukemia
- Trial name
- NCT01962636
- Testing
- Fludarabine, Cyclophosphamide, Total Body Irradiation
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
This is a multi-center, non-randomized, 3-cohort, phase II trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel…
- Conditions
- Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
- Trial name
- NCT04840264
- Testing
- Docetaxel, Oxaliplatin, Fluorouracil
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Von Hippel-Lindau Syndrome, Renal Cell Carcinoma
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
The goal of this clinical research study is to learn if sunitinib malate (SU011248) can help to control VHL. The safety of this drug will also be studied.
- Conditions
- Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
- Trial name
- NCT00330564
- Testing
- SU011248
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma in Relapse, Multiple Myeloma
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment.
- Trial name
- NCT02666209
- Testing
- Ulocuplumab, Lenalidomide, Bortezomib
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.